| Autor: |
Alm, Richard A., Lahiri, Sushmita D., Kutschke, Amy, Otterson, Linda G., McLaughlin, Robert E., Whiteaker, James D., Lewis, Lisa A., Su, Xiaohong, Huband, Michael D., Gardner, Humphrey, Mueller, John P. |
| Zdroj: |
Antimicrobial Agents and Chemotherapy; December 2014, Vol. 59 Issue: 3 p1478-1486, 9p |
| Abstrakt: |
ABSTRACTThe unmet medical need for novel intervention strategies to treat Neisseria gonorrhoeaeinfections is significant and increasing, as rapidly emerging resistance in this pathogen is threatening to eliminate the currently available treatment options. AZD0914 is a novel bacterial gyrase inhibitor that possesses potent in vitroactivities against isolates with high-level resistance to ciprofloxacin and extended-spectrum cephalosporins, and it is currently in clinical development for the treatment of N. gonorrhoeaeinfections. The propensity to develop resistance against AZD0914 was examined in N. gonorrhoeaeand found to be extremely low, a finding supported by similar studies with Staphylococcus aureus. The genetic characterization of both first-step and second-step mutants that exhibited decreased susceptibilities to AZD0914 identified substitutions in the conserved GyrB TOPRIM domain, confirming DNA gyrase as the primary target of AZD0914 and providing differentiation from fluoroquinolones. The analysis of available bacterial gyrase and topoisomerase IV structures, including those bound to fluoroquinolone and nonfluoroquinolone inhibitors, has allowed the rationalization of the lack of cross-resistance that AZD0914 shares with fluoroquinolones. Microbiological susceptibility data also indicate that the topoisomerase inhibition mechanisms are subtly different between N. gonorrhoeaeand other bacterial species. Taken together, these data support the progression of AZD0914 as a novel treatment option for the oral treatment of N. gonorrhoeaeinfections. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
